Tamura Yasushi, Yamagiwa Satoshi, Aoki Yohei, Kurita So, Suda Takeshi, Ohkoshi Shogo, Nomoto Minoru, Aoyagi Yutaka
Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Japan.
Dig Dis Sci. 2009 Nov;54(11):2530-7. doi: 10.1007/s10620-008-0642-y. Epub 2008 Dec 18.
The association between serum alpha-fetoprotein (AFP) levels during and after interferon (IFN) therapy and the development of hepatocellular carcinoma (HCC) was evaluated in patients with chronic hepatitis C (CHC). A total of 263 patients treated by IFN with or without ribavirin were enrolled in the study. Serum AFP levels during and after IFN therapy were investigated retrospectively, and statistical analysis was performed to identify the factors associated with HCC development. During IFN therapy, serum AFP levels significantly decreased, regardless of virologic response to treatment. Increased serum AFP levels (>or=10 ng/ml) at the end of IFN therapy (EOT) was a close-to-significant variable affecting the development of HCC (P = 0.057), and a significantly higher cumulative incidence of HCC was seen in patients with increased serum AFP levels at EOT (P = 0.021). Serum AFP level at EOT is a possible predictor of HCC in CHC patients after IFN therapy.
在慢性丙型肝炎（CHC）患者中，评估了干扰素（IFN）治疗期间及之后血清甲胎蛋白（AFP）水平与肝细胞癌（HCC）发生之间的关联。共有263例接受IFN联合或不联合利巴韦林治疗的患者纳入该研究。对IFN治疗期间及之后的血清AFP水平进行回顾性研究，并进行统计分析以确定与HCC发生相关的因素。在IFN治疗期间，无论对治疗的病毒学反应如何，血清AFP水平均显著下降。IFN治疗结束时（EOT）血清AFP水平升高（≥10 ng/ml）是影响HCC发生的一个接近显著的变量（P = 0.057），且EOT时血清AFP水平升高的患者中HCC的累积发生率显著更高（P = 0.021）。EOT时的血清AFP水平可能是CHC患者IFN治疗后HCC的一个预测指标。
